Trial Profile

A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDH 305 (Primary)
Indications Acute myeloid leukaemia; Cancer; Glioma; Myelodysplastic syndromes; Solid tumours
Focus Adverse reactions; First in man
Sponsors Novartis; Novartis Pharmaceuticals Corporation

Most Recent Events

25 Mar 2025 Planned End Date changed from 24 Oct 2025 to 1 Feb 2026.
26 Feb 2024 Planned End Date changed from 25 Oct 2024 to 24 Oct 2025.
01 Mar 2023 Status changed from active, no longer recruiting to suspended according to results published in the Journal of Cancer Research and Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com